论文部分内容阅读
目的观察雷贝拉唑联合莫沙比利治疗反流性食管炎的疗效。方法将36例经内镜证实的反流性食管炎患者随机组合分为治疗组(18例)和对照组(18例)。分别予以雷贝拉唑联合莫沙比利和雷尼替丁联合莫沙比利治疗,疗程均为8周。结果治疗组4周、8周临床有效率为77.8%、94.4%,对照组的相应值为61.1%、83.3%。内镜下有效率为治疗组88.9%,对照组70%。结论雷贝拉唑联合莫沙比利治疗反流性食管炎的疗效优于雷尼替丁联合莫沙比利,是目前治疗反流性食管炎的较理想方法。
Objective To observe the efficacy of rabeprazole and mosapride in the treatment of reflux esophagitis. Methods Thirty - six patients with reflux esophagitis confirmed by endoscopy were randomly divided into treatment group (18 cases) and control group (18 cases). Respectively, rabeprazole combined mosapride and ranitidine combined moshabi treatment, were treated for 8 weeks. Results The effective rates of the treatment group were 77.8% and 94.4% at 4 weeks and 8 weeks, respectively, and those in the control group were 61.1% and 83.3% respectively. Efficacy of endoscopic treatment group 88.9%, control group 70%. Conclusion The efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis is better than that of ranitidine combined with mosapride, which is the ideal method for the treatment of reflux esophagitis.